Multivariate Markov models for the conditional probability of toxicity in phase II trials
{{output}}
In addition to getting a preliminary assessment of efficacy, phase II trials can also help to determine dose(s) that have an acceptable toxicity profile over repeated cycles as well as identify subgroups with particularly poor toxicity profiles. Correct modeli... ...